Core Viewpoint - Achieve Life Sciences Inc. is advancing its cytisinicline drug for nicotine dependence through a partnership with Adare Pharma Solutions for U.S. manufacturing, aiming for a commercial launch in the first half of 2027, while facing challenges that have delayed its timeline from 2026 to 2027 [2][5]. Group 1: Partnership and Manufacturing - The company has partnered with Adare Pharma Solutions to manufacture cytisinicline, which is intended to address nicotine dependence [2]. - This partnership is expected to mitigate risks associated with international importation and potentially lower costs, including tariffs [3]. - The technology transfer to Adare has already commenced [3]. Group 2: Financial Performance - Achieve Life Sciences reported a total net loss of $14.7 million for Q4 2025 and $54.7 million for the full year, with cash and marketable securities amounting to $36.4 million as of December 31, 2025 [4]. Group 3: Regulatory and Clinical Developments - The U.S. FDA inspected a manufacturer related to the cytisinicline application and identified two observations regarding solid oral dose manufacturing, which the company is currently addressing [5]. - New clinical data indicates that cytisinicline shows significant quitting success after 6 and 12 weeks, regardless of prior smoking cessation medication use or previous quit attempts [6]. Group 4: Market Position and ETF Exposure - Cytisinicline is positioned to potentially become the first FDA-approved smoking cessation therapy in nearly 20 years, with a report suggesting it is likely the best therapy for quitting smoking [7]. - Achieve Life Sciences holds a 6.73% weight in the Simplify Propel Opportunities ETF [7]. - The stock price of Achieve Life Sciences was up 0.13% at $2.824 during premarket trading [7].

Core Viewpoint - Achieve Life Sciences is advancing its cytisinicline program for nicotine dependence treatment, announcing a partnership with Adare Pharma Solutions for manufacturing, and is on track for a potential U.S. commercial launch in the first half of 2027 [1][3][4]. Company Developments - Achieve has made significant progress towards regulatory approval, with the FDA accepting the New Drug Application (NDA) for cytisinicline, targeting a PDUFA date of June 20, 2026 [4][8]. - The company completed the ORCA-OL long-term exposure trial with 334 participants, providing extensive safety data that exceeds FDA requirements [4]. - Cytisinicline has been selected for the FDA Commissioner's National Priority Voucher for e-cigarette cessation, which will facilitate expedited review [4][10]. Partnership and Manufacturing - The partnership with Adare Pharma Solutions aims to reduce risks associated with international pharmaceutical importation and lower costs, including potential tariffs [2][3]. - Achieve has begun technology transfer to Adare, enhancing supply chain redundancy and U.S.-based contingency capacity [3][4]. Financial Performance - As of December 31, 2025, Achieve reported cash, cash equivalents, and marketable securities totaling $36.4 million [6]. - Total operating expenses for Q4 2025 were $14.7 million, with a net loss of $14.7 million for the quarter and $54.7 million for the full year [6][17]. Clinical and Scientific Advancements - Achieve's clinical program demonstrates cytisinicline's potential to address nicotine dependence, with findings indicating efficacy regardless of prior treatment history [5][11]. - Recent data published in JAMA Internal Medicine reaffirm cytisinicline's efficacy and tolerability for smoking cessation [4][5].

Core Insights - Achieve Life Sciences, Inc. announced new data indicating that cytisinicline is effective in helping individuals quit smoking, including those who have previously failed with other cessation medications and regardless of their quit attempt history [1][4][3] Group 1: Clinical Data and Efficacy - A pooled Phase 3 analysis involving over 1,600 participants demonstrated high quit rates with cytisinicline after 6 and 12 weeks of treatment, showing effectiveness across various prior treatment histories [1][3] - The analysis included participants with different backgrounds, such as those who had used varenicline, bupropion, and nicotine replacement therapy, and categorized them based on their number of previous quit attempts [3][4] - Cytisinicline was shown to benefit individuals regardless of their prior quit history, providing hope for those who have faced setbacks in their attempts to quit smoking [4][3] Group 2: Patient Experience and Safety - Late-breaking survey data from the ORCA-OL study highlighted participant experiences with extended use of cytisinicline, contributing to a comprehensive understanding of its impact on quitting smoking [2][4] - Participants reported meaningful benefits from cytisinicline, including successful quitting and improvements in physical health, emphasizing the importance of patient experience in smoking cessation efforts [5][4] Group 3: Regulatory and Market Context - Achieve Life Sciences is focused on the global development and commercialization of cytisinicline for nicotine dependence, with a New Drug Application submitted to the FDA that is currently under review [7] - The FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026, for the cytisinicline application, which is based on successful Phase 3 studies and an open-label safety study [7] - The company has also completed a Phase 2 study for vaping cessation, indicating a broader strategy to address nicotine dependence beyond traditional smoking [7]

Core Insights - Achieve Life Sciences, Inc. is focused on the development and commercialization of cytisinicline as a treatment for nicotine dependence and smoking cessation [1][3] - The company will report its Q3 2025 financial results and provide updates on the cytisinicline program on November 6, 2025 [1] - The FDA has accepted Achieve's New Drug Application for cytisinicline, with a PDUFA date set for June 20, 2026 [3] Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company addressing the global smoking health crisis through cytisinicline [3] - Cytisinicline has shown efficacy in two completed Phase 3 studies and an open-label safety study for smoking cessation [3] - The company has also completed a Phase 2 study for vaping cessation and had a successful end-of-Phase 2 meeting with the FDA [3] Industry Context - Approximately 29 million adults in the U.S. smoke combustible cigarettes, with tobacco use being the leading cause of preventable death [4] - There are around 17 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for nicotine e-cigarette cessation [5] - The FDA has recognized the need for treatments in this area by awarding a National Priority Voucher and granting Breakthrough Therapy designation [5] Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors to help treat nicotine addiction [6] - The product is still investigational and has not yet received FDA approval for any indication in the U.S. [6]

Core Insights - Achieve Life Sciences has appointed Erik Atkisson as Chief Legal Officer, bringing over 25 years of legal expertise in the biopharmaceutical sector to the company [1][2] Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline for nicotine dependence treatment [3] - The company submitted a New Drug Application (NDA) for cytisinicline to the FDA in June 2025, which has been accepted for review with a PDUFA date set for June 20, 2026 [3] Product Information - Cytisinicline is a plant-derived alkaloid that interacts with nicotinic acetylcholine receptors to help treat nicotine dependence for both smoking and vaping cessation [5][6] - The drug has been granted Breakthrough Therapy designation by the FDA, addressing a significant unmet need in nicotine e-cigarette cessation [4] Market Context - Approximately 29 million adults in the U.S. smoke combustible cigarettes, with tobacco use being the leading cause of preventable death globally [4] - There are around 17 million adults in the U.S. who use e-cigarettes, highlighting the growing need for effective cessation treatments [4]

Core Insights - Achieve Life Sciences has received FDA acceptance for its New Drug Application (NDA) for cytisinicline, marking a significant step towards potentially the first new FDA-approved pharmacotherapy for smoking cessation in two decades, with a PDUFA target date set for June 20, 2026 [2][4]. Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline to address nicotine dependence and smoking cessation [5]. - The company has conducted extensive research, with over 2,000 clinical trial participants contributing to the evidence supporting cytisinicline's efficacy [3]. Clinical Trials and Efficacy - The ORCA-2 and ORCA-3 Phase 3 clinical trials demonstrated that cytisinicline, administered for either 6 or 12 weeks alongside standard behavioral support, resulted in significantly higher smoking abstinence rates compared to placebo [3]. - Safety data from the trials included over 400 participants with at least six months of cumulative exposure to cytisinicline, showing no new safety concerns [3]. Public Health Impact - Smoking is the leading cause of preventable death in the U.S., claiming nearly half a million lives annually and costing the economy over $600 billion each year [4][6]. - Approximately 15 million Americans attempt to quit smoking each year, highlighting the need for effective cessation tools [4]. Market Opportunity - There are about 29 million adults in the U.S. who smoke combustible cigarettes, and the company aims to provide a new treatment option for this population [6]. - Additionally, there are around 17 million adults using e-cigarettes, with no FDA-approved treatments currently available for nicotine e-cigarette cessation, indicating a significant unmet need [7]. Product Mechanism - Cytisinicline is a plant-derived alkaloid that interacts with nicotinic acetylcholine receptors in the brain, helping to reduce nicotine cravings and the satisfaction associated with nicotine products [8].

Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence and smoking cessation [3] - The company submitted its New Drug Application to the FDA for cytisinicline in June 2025, based on two completed Phase 3 studies and a fully enrolled open-label safety study [3] - Achieve has also completed a Phase 2 study for cytisinicline in vaping cessation and had a successful end-of-Phase 2 meeting with the FDA for a future vaping indication [3] Industry Context - Approximately 29 million adults in the United States smoke combustible cigarettes, with tobacco use being the leading cause of preventable death, responsible for over 8 million deaths worldwide and nearly 500,000 deaths annually in the U.S. [4] - More than 87% of lung cancer deaths, 61% of pulmonary disease deaths, and 32% of coronary heart disease deaths are attributable to smoking and secondhand smoke exposure [4] - There are around 17 million adults in the U.S. who use e-cigarettes, with 1.6 million middle and high school students reporting e-cigarette use in 2024 [4] Product Information - Cytisinicline is a plant-based alkaloid with a high binding affinity to nicotinic acetylcholine receptors, believed to aid in treating nicotine addiction by reducing craving symptoms and the satisfaction associated with nicotine products [5] - Cytisinicline is currently an investigational product candidate and has not yet been approved by the FDA for any indication in the United States [5] - The FDA has granted Breakthrough Therapy designation to cytisinicline to address the critical need for treatments specifically aimed at nicotine e-cigarette cessation [4]

Core Viewpoint - Achieve Life Sciences, Inc. has successfully closed a public offering of 15 million shares of common stock, raising gross proceeds of $45 million to advance the development of cytisinicline for nicotine dependence treatment [1][2]. Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence, with a New Drug Application submitted to the FDA in June 2025 [5]. - The company has completed two Phase 3 studies and an open-label safety study for cytisinicline, and has also conducted a Phase 2 study for vaping cessation [5]. Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, aimed at reducing nicotine cravings and the satisfaction derived from nicotine products [7]. - Approximately 29 million adults in the U.S. smoke combustible cigarettes, and tobacco use is the leading cause of preventable death globally, with over 8 million deaths annually [6]. - There are currently no FDA-approved treatments specifically for nicotine e-cigarette cessation, highlighting a critical need that cytisinicline aims to address [6]. Financial Details - The public offering included 15 million shares at a price of $3.00 per share, along with warrants to purchase up to 16,766,666 additional shares [1]. - Proceeds from the offering will be used for advancing cytisinicline towards FDA marketing approval and for general corporate purposes [2].

Core Viewpoint - Achieve Life Sciences, Inc. is conducting a public offering of 15 million shares of common stock and accompanying warrants at a price of $3.00 per share, aiming to raise approximately $45 million to support the development of cytisinicline for nicotine dependence treatment [1][4]. Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence and smoking cessation [7]. - The company submitted a New Drug Application to the FDA for cytisinicline in June 2025, based on successful Phase 3 studies and an open-label safety study [7]. Offering Details - The public offering includes 15 million shares and warrants, with an additional 2.25 million shares available for underwriters to purchase [1][3]. - Each common warrant can be exercised for common stock at $3.00 or for pre-funded warrants at $2.999, expiring five years from issuance [2]. Financial Aspects - The gross proceeds from the offering are expected to be around $45 million, which will be used for advancing cytisinicline towards FDA approval and for general corporate purposes [4]. - The offering is expected to close around June 30, 2025, pending customary closing conditions [3]. Market Context - There are approximately 29 million adult smokers in the U.S., with tobacco use being the leading cause of preventable death [8]. - Cytisinicline has been granted Breakthrough Therapy designation by the FDA to address the need for effective treatments for nicotine e-cigarette cessation, as there are currently no FDA-approved options for this indication [9].

Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence and smoking cessation [5] - The company submitted its New Drug Application to the FDA for cytisinicline in June 2025, based on two completed Phase 3 studies and a fully enrolled open-label safety study [5] Offering Details - Achieve Life Sciences announced a proposed underwritten public offering to sell shares of its common stock and accompanying common warrants, with an option for underwriters to purchase an additional 15% of the shares [1][2] - The proceeds from the offering are intended to fund the advancement of cytisinicline through potential FDA marketing approval and for working capital and general corporate purposes [2] Market Context - Approximately 29 million adults in the U.S. smoke combustible cigarettes, with tobacco use being the leading cause of preventable death, responsible for over eight million deaths globally and nearly half a million in the U.S. annually [6] - There are around 17 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for nicotine e-cigarette cessation, highlighting a critical need for effective solutions [7] Product Information - Cytisinicline is a plant-based alkaloid with a high binding affinity to nicotinic acetylcholine receptors, believed to aid in treating nicotine addiction by reducing craving symptoms and the satisfaction associated with nicotine products [8][9] - Cytisinicline has been granted Breakthrough Therapy designation by the FDA to address the urgent need for treatments for nicotine dependence [7]